In final draft guidance published today, NICE has recommended degarelix (Firmagon, Ferring Pharmaceuticals), as an option for treating advanced hormone dependent prostate cancer in people with spinal metastases who present with signs or symptoms of spinal cord compression.

Prostate cancer is common - more than 37,000 men are diagnosed with prostate cancer every year in England and Wales. Metastatic prostate cancer describes when the primary cancer has spread from the prostate to other parts of the body, such as the bone.

Commenting on the draft guidance, Professor Carole Longson, Director, Centre for Health Technology Evaluation, NICE said: â€œDegarelix is a hormone therapy drug that provides an important benefit for people with cancer that has spread to the spine and presents with signs or symptoms of spinal cord compression. We are pleased to be able to recommend degarelix as a treatment option in this population.”

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICEDraftGuidanceRecommendsATreatmentForProstateCancer...